Stockreport

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients [Yahoo! Finance]

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Patient enrolment for Phase IIb study is ongoing in Europe and Israel RAMAT GAN, Israel, April 03, 2024 BUSINESS WIRE )--Can-Fite BioPharma Ltd. (NYSE American: CANF) [Read more]